The HTRA2 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line, engineered to disrupt the HTRA2 gene. This knockout model provides a heterogeneous pool of cells with targeted loss of HTRA2 function, enabling robust loss-of-function studies without single-cell clonal selection. The polyclonal format minimizes clonal artifacts and preserves population-level genetic diversity, making it suitable for pooled analyses of HTRA2-dependent cellular processes.
The parental HT29 cell line originates from a primary colorectal adenocarcinoma of a 44-year-old female and serves as a well-characterized model of intestinal epithelial biology. These cells are mucus-secreting colon epithelial cells that retain features of differentiated enterocytes, including the ability to form polarized monolayers and produce mucins. HT29 cells are widely employed to investigate intestinal barrier function, epithelial differentiation, oncogenic signaling pathways, and colorectal cancer pathogenesis, offering a physiologically relevant background for studying HTRA2 function in colon epithelial cells.
HTRA2 encodes a mitochondrial serine protease with dual roles in maintaining mitochondrial proteostasis and promoting apoptosis. Under basal conditions, HTRA2 functions as a quality control protease within the mitochondrial intermembrane space, participating in the mitochondrial unfolded protein response (UPRmt) and interacting with chaperones such as HSP60. Upon mitochondrial stress or apoptotic stimuli, HTRA2 is released into the cytosol in a process regulated by PINK1 kinase and PARK2 (Parkin). In the cytosol, HTRA2 directly binds and cleaves inhibitor of apoptosis proteins (IAPs) including XIAP, cIAP1, and cIAP2, thereby relieving their inhibition of caspases such as CASP3 and CASP9, and promoting caspase-dependent cell death. This pathway is integrated with Bcl-2 family members like BAX and BAK that govern mitochondrial outer membrane permeabilization.
In the HT29 colorectal cancer model, HTRA2 disruption allows dissection of its role in apoptosis sensitivity and mitochondrial homeostasis within an oncogenic background. HT29 cells harbor mutations in key cancer-related genes (e.g., TP53, APC), making them a relevant system to study how HTRA2 loss impacts chemoresistance, stress responses, and tumor cell survival. Because HT29 cells exhibit spontaneous differentiation and mucus secretion, this model can also address HTRA2’s contribution to epithelial differentiation programs and barrier integrity under genotoxic or metabolic stress. Furthermore, the link between HTRA2 dysfunction and Parkinson’s disease (designated PARK13) provides an opportunity to explore mitochondrial quality control mechanisms in a non-neuronal epithelial context, potentially uncovering common stress response pathways.
This polyclonal knockout cell population is well-suited for a range of experimental applications. Researchers can employ Western blotting to confirm HTRA2 protein loss, and use Annexin V/PI flow cytometry or caspase-3/7 activity assays to quantify apoptosis following treatment with chemotherapeutics or mitochondrial stressors. JC-1 mitochondrial membrane potential assays and cell viability (resazurin) measurements permit evaluation of mitochondrial health and drug sensitivity. The model supports colony formation and scratch wound migration assays to assess tumorigenic properties, while co-immunoprecipitation of HTRA2 with XIAP can probe protein interactions. These cells facilitate drug screening for colon cancer therapies targeting IAP pathways, mechanistic studies of Parkinson-related mitochondrial dysfunction, and evaluation of caspase-independent cell death mechanisms. For additional details, please contact Ascent Research.
